WO2019186276A2 - Antibody-based methods of detecting and treating alzheimer's disease - Google Patents

Antibody-based methods of detecting and treating alzheimer's disease Download PDF

Info

Publication number
WO2019186276A2
WO2019186276A2 PCT/IB2019/000358 IB2019000358W WO2019186276A2 WO 2019186276 A2 WO2019186276 A2 WO 2019186276A2 IB 2019000358 W IB2019000358 W IB 2019000358W WO 2019186276 A2 WO2019186276 A2 WO 2019186276A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
amino acid
acid sequence
antibody
chain variable
Prior art date
Application number
PCT/IB2019/000358
Other languages
English (en)
French (fr)
Other versions
WO2019186276A8 (en
WO2019186276A3 (en
Inventor
Jozef Hanes
Eva Kontsekova
Andrej KOVAC
Norbert ZILKA
Original Assignee
Axon Neuroscience Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2020135052A priority Critical patent/RU2020135052A/ru
Priority to JP2020551506A priority patent/JP2021520777A/ja
Priority to BR112020018868-9A priority patent/BR112020018868A2/pt
Priority to MX2020009991A priority patent/MX2020009991A/es
Application filed by Axon Neuroscience Se filed Critical Axon Neuroscience Se
Priority to SG11202008098TA priority patent/SG11202008098TA/en
Priority to EP19732436.1A priority patent/EP3774887A2/en
Priority to CN201980029711.2A priority patent/CN112236452A/zh
Priority to KR1020207030584A priority patent/KR20200144551A/ko
Priority to CA3095443A priority patent/CA3095443A1/en
Priority to US15/733,660 priority patent/US20210139568A1/en
Priority to AU2019244481A priority patent/AU2019244481A1/en
Publication of WO2019186276A2 publication Critical patent/WO2019186276A2/en
Publication of WO2019186276A3 publication Critical patent/WO2019186276A3/en
Priority to IL277577A priority patent/IL277577A/en
Publication of WO2019186276A8 publication Critical patent/WO2019186276A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PCT/IB2019/000358 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease WO2019186276A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EP19732436.1A EP3774887A2 (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease
BR112020018868-9A BR112020018868A2 (pt) 2018-03-28 2019-03-27 métodos baseados em anticorpo para detectar e tratar doença de alzheimer
MX2020009991A MX2020009991A (es) 2018-03-28 2019-03-27 Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer.
KR1020207030584A KR20200144551A (ko) 2018-03-28 2019-03-27 알츠하이머병을 검출하고 치료하는 항체-기반 방법
SG11202008098TA SG11202008098TA (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease
JP2020551506A JP2021520777A (ja) 2018-03-28 2019-03-27 アルツハイマー病を検出および処置するための抗体に基づく方法
CN201980029711.2A CN112236452A (zh) 2018-03-28 2019-03-27 检测和治疗阿尔茨海默氏病的基于抗体的方法
RU2020135052A RU2020135052A (ru) 2018-03-28 2019-03-27 Способы выявления и лечения болезни альцгеймера на основе антител
CA3095443A CA3095443A1 (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease
US15/733,660 US20210139568A1 (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease
AU2019244481A AU2019244481A1 (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating Alzheimer's disease
IL277577A IL277577A (en) 2018-03-28 2020-09-24 Antibody-based methods for the detection and treatment of Alzheimer's disease

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862649208P 2018-03-28 2018-03-28
US62/649,208 2018-03-28
US201862664662P 2018-04-30 2018-04-30
US62/664,662 2018-04-30
US201862703299P 2018-07-25 2018-07-25
US62/703,299 2018-07-25

Publications (3)

Publication Number Publication Date
WO2019186276A2 true WO2019186276A2 (en) 2019-10-03
WO2019186276A3 WO2019186276A3 (en) 2020-02-27
WO2019186276A8 WO2019186276A8 (en) 2020-10-15

Family

ID=66999856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/000358 WO2019186276A2 (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease

Country Status (12)

Country Link
EP (1) EP3774887A2 (ko)
JP (1) JP2021520777A (ko)
KR (1) KR20200144551A (ko)
CN (1) CN112236452A (ko)
AU (1) AU2019244481A1 (ko)
BR (1) BR112020018868A2 (ko)
CA (1) CA3095443A1 (ko)
IL (1) IL277577A (ko)
MX (1) MX2020009991A (ko)
RU (1) RU2020135052A (ko)
SG (1) SG11202008098TA (ko)
WO (1) WO2019186276A2 (ko)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021048619A2 (en) 2019-09-09 2021-03-18 Axon Neuroscience Se Biomarkers and treatments of alzheimer's disease and mild cognitive impairment
WO2022132923A1 (en) * 2020-12-16 2022-06-23 Voyager Therapeutics, Inc. Tau binding compounds
WO2022176959A1 (en) * 2021-02-19 2022-08-25 Eisai R&D Management Co., Ltd. Anti-pt217 tau antibody
US11492393B2 (en) 2016-05-02 2022-11-08 Prothena Biosciences Limited Tau immunotherapy
US11584791B2 (en) 2016-05-02 2023-02-21 Prothena Biosciences Limited Antibodies recognizing tau
US11643457B2 (en) 2013-03-13 2023-05-09 Prothena Biosciences Limited Tau immunotherapy
US11926659B2 (en) 2019-03-03 2024-03-12 Prothena Biosciences Limited Antibodies recognizing tau
US11958896B2 (en) 2017-05-02 2024-04-16 Prothena Biosciences Limited Antibodies recognizing tau

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117003863A (zh) * 2022-04-28 2023-11-07 厦门大学 针对p-tau 217的抗体及其用途
CN114778856B (zh) * 2022-05-30 2023-03-17 苏州宇测生物科技有限公司 磷酸化tau蛋白检测试剂盒

Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5122368A (en) 1988-02-11 1992-06-16 Bristol-Myers Squibb Company Anthracycline conjugates having a novel linker and methods for their production
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
WO1993010151A1 (en) 1991-11-22 1993-05-27 Immunex Corporation Receptor for oncostatin m and leukemia inhibitory factor
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
WO1997004801A1 (en) 1995-07-27 1997-02-13 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5712120A (en) 1994-06-30 1998-01-27 Centro De Immunologia Molecular Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains, compositions containing them
US5824805A (en) 1995-12-22 1998-10-20 King; Dalton Branched hydrazone linkers
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US20020025313A1 (en) 1992-07-27 2002-02-28 Micklus Michael J. Targeting of liposomes to the blood-brain barrier
US20020034765A1 (en) 1991-05-17 2002-03-21 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US20020038086A1 (en) 2000-07-27 2002-03-28 Hynynen Kullervo H. Blood-brain barrier opening
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
US20030153043A1 (en) 1997-05-21 2003-08-14 Biovation Limited Method for the production of non-immunogenic proteins
WO2004007547A2 (en) 2002-07-12 2004-01-22 Axon Neuroscience Forschungs- Und Entwicklungs Gmbh Truncated tau proteins
US20040131692A1 (en) 2001-05-05 2004-07-08 Joerg Kreuter Nanoparticles made of protein with coupled apolipoprotein e for penetration of the blood-brain barrier and methods for the production thereof
WO2004058258A1 (en) 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US20040204354A1 (en) 2002-12-03 2004-10-14 Thomas Nelson Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
US20050238649A1 (en) 2003-11-06 2005-10-27 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2006034488A2 (en) 2004-09-23 2006-03-30 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20080050383A1 (en) 2006-03-29 2008-02-28 New York University Immunotherapy for clearing pathological tau conformers
US7566771B1 (en) 1989-12-21 2009-07-28 Celltech R&D Limited Humanised antibodies
WO2016079597A1 (en) 2014-11-19 2016-05-26 Axon Neuroscience Se Humanized tau antibodies in alzheimer's disease
US9518101B2 (en) 2011-09-19 2016-12-13 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
US20080220449A1 (en) * 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
US8093018B2 (en) * 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
WO2011016239A1 (en) * 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
MY186066A (en) * 2011-12-20 2021-06-18 Janssen Biotech Inc Anti-phf-tau antibodies and their uses
US8853505B2 (en) * 2012-02-27 2014-10-07 Syngenta Participations Ag Variety corn line AA2205
US8980270B2 (en) * 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
RU2018129180A (ru) * 2016-02-05 2020-03-05 Цзянсу Хэнжуй Медицин Ко., Лтд. Тромбиновое антитело, антиген-связывающий фрагмент и их фармацевтическое применение

Patent Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US5648260A (en) 1987-03-18 1997-07-15 Scotgen Biopharmaceuticals Incorporated DNA encoding antibodies with altered effector functions
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5122368A (en) 1988-02-11 1992-06-16 Bristol-Myers Squibb Company Anthracycline conjugates having a novel linker and methods for their production
US7566771B1 (en) 1989-12-21 2009-07-28 Celltech R&D Limited Humanised antibodies
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5506206A (en) 1990-04-23 1996-04-09 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5686416A (en) 1991-04-23 1997-11-11 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US20040253645A1 (en) 1991-05-17 2004-12-16 Daugherty Bruce L. Method for reducing the immunogenicity of antibody variable domains
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US20020034765A1 (en) 1991-05-17 2002-03-21 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
WO1993010151A1 (en) 1991-11-22 1993-05-27 Immunex Corporation Receptor for oncostatin m and leukemia inhibitory factor
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US20020025313A1 (en) 1992-07-27 2002-02-28 Micklus Michael J. Targeting of liposomes to the blood-brain barrier
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5712120A (en) 1994-06-30 1998-01-27 Centro De Immunologia Molecular Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains, compositions containing them
WO1997004801A1 (en) 1995-07-27 1997-02-13 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US5824805A (en) 1995-12-22 1998-10-20 King; Dalton Branched hydrazone linkers
US20030153043A1 (en) 1997-05-21 2003-08-14 Biovation Limited Method for the production of non-immunogenic proteins
US20020038086A1 (en) 2000-07-27 2002-03-28 Hynynen Kullervo H. Blood-brain barrier opening
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
US20040131692A1 (en) 2001-05-05 2004-07-08 Joerg Kreuter Nanoparticles made of protein with coupled apolipoprotein e for penetration of the blood-brain barrier and methods for the production thereof
WO2004007547A2 (en) 2002-07-12 2004-01-22 Axon Neuroscience Forschungs- Und Entwicklungs Gmbh Truncated tau proteins
US20040204354A1 (en) 2002-12-03 2004-10-14 Thomas Nelson Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
WO2004058258A1 (en) 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050238649A1 (en) 2003-11-06 2005-10-27 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2006034488A2 (en) 2004-09-23 2006-03-30 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20080050383A1 (en) 2006-03-29 2008-02-28 New York University Immunotherapy for clearing pathological tau conformers
US9518101B2 (en) 2011-09-19 2016-12-13 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
WO2016079597A1 (en) 2014-11-19 2016-05-26 Axon Neuroscience Se Humanized tau antibodies in alzheimer's disease

Non-Patent Citations (137)

* Cited by examiner, † Cited by third party
Title
"Catalogue of Cell Lines and Hybridomas", 1985
"Remington's Pharmaceutical Sciences", 2006
ANDERSSON ET AL.: "CSF biomarker levels in early and late onset Alzheimer's disease", NEUROBIOL AGING, vol. 30, 2008, pages 1895 - 1901, XP026692382, DOI: doi:10.1016/j.neurobiolaging.2008.02.007
ANDREASEN ET AL., ARCH. NEUROL., vol. 56, 1999, pages 673 - 680
ANDREASEN ET AL.: "Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment", ACTA NEUROL. SCAND. SUPPL., vol. 179, 2003, pages 47 - 51, XP002284308, DOI: doi:10.1034/j.1600-0404.107.s179.9.x
ARAI ET AL., JAGS, vol. 45, 1997, pages 1228 - 31
ASUNI ET AL.: "Immunotherapy Targeting Pathological Tau Conformers In a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements", THE JOURNAL OF NEUROSCIENCE, vol. 27, no. 34, 2007, pages 9115 - 9129, XP002606710, DOI: doi:10.1523/JNEUROSCI.2361-07.2007
BARRIO ET AL.: "The Irony of PET Tau Probe Specificity", J. NUCL. MED., vol. 59, no. 1, 2018, pages 115 - 116
BAUM ET AL., EMBO J., vol. 13, 1994, pages 3992 - 4001
BEJANIN ET AL.: "Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease", BRAIN, vol. 140, no. 12, 2017, pages 3286 - 3300
BEYCHOK: "Cells of Immunoglobulin Synthesis", 1979, ACADEMIC PRESS
BLENNOW: "CSF markers for incipient Alzheimer's disease", LANCET NEUROL., vol. 2, 2005, pages 605 - 613, XP004811238, DOI: doi:10.1016/S1474-4422(03)00530-1
BLENNOWHAMPEL: "CSF markers for incipient Alzheimer's disease", LANCET NEUROL., vol. 2, 2003, pages 605 - 613, XP004811238, DOI: doi:10.1016/S1474-4422(03)00530-1
BLOMBERG ET AL., NEUROSCI. LETT., vol. 214, 1996, pages 163 - 166
BOUWMAN ET AL.: "Longtitudinal changes of CSF biomarkers in memory clinic patients", NEUROLOGY, vol. 69, 2007, pages 1006 - 1011
BRAAK ET AL.: "Neuropathological stageing of Alzheimer-related changes", ACTA NEUROPATHOBGICA, vol. 82, no. 4, 1991, pages 239 - 59
BRAAK ET AL.: "Neuropathological stageirig of Alzheimer-related changes", ACTA NEUROPATHOBGICA, vol. 82, no. 4, 1991, pages 239 - 59
BRAAKBRAAK: "Neuropathological stageing of Alzheimer-related changes", ACTA NEUROPATHOL, vol. 82, 1991, pages 239 - 59
BURNS ET AL., ALZHEIMER'S DISEASE, THE LANCET, vol. 360, 13 July 2002 (2002-07-13)
CARTER ET AL., PNAS USA, vol. 89, 1992, pages 4285
CAVEDO ET AL.: "The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations", J. PREV. ALZHEIMER'S DIS., vol. 3, 2014, pages 181 - 202
CHEUNG ET AL., VIROLOGY, vol. 176, 1990, pages 546
CHOI ET AL., DEVELOPMENT OF TAU PET IMAGING LIGANDS AND THEIR UTILITY IN PRECLINICAL AND CLINICAL STUDIES, vol. 52, no. 1, 2018, pages 24 - 30
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 196901 - 917
CITRON ET AL.: "Alzheimer's disease: strategies for disease modification", NATURE REVIEWS, vol. 9, 2010, pages 397
CLOTHIA ET AL., NATURE, vol. 342, 1989, pages 878 - 883
COWAN, C.M.MUDHER, A.: "Are tau aggregates toxic or protective in tauopathies?", FRONTIERS IN NEUROLOGY, vol. 4, 2013, pages 114
CSOKOVA ET AL.: "Rapid purification of truncated tau proteins: model approach to purification of functionally active fragments of disordered proteins, implication for neurodegenerative diseases", PROTEIN EXPRESSION AND PURIFICATION, vol. 35, 2004, pages 366 - 372, XP004506575, DOI: doi:10.1016/j.pep.2004.01.012
CUMMINGS ET AL.: "Alzheimer's disease drug development pipeline: 2017", ALZHEIMER'S & DEMENTIA, vol. 3, 2017, pages 367 - 384
CUMMINGS ET AL.: "Alzheimer's disease drug development pipeline: 2017", ALZHEIMER'S & DEMENTIA: TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, vol. 3, 2017, pages 367 - 384
DELEON ET AL., NEUROBIOL. AGING, vol. 27, 2006, pages 394 - 401
DELEON ET AL.: "Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment", NEUROSCI LETT., vol. 333, 2004, pages 183 - 186
DICKEY ET AL.: "Development of a High Throughput Drug Screening Assay for the Detection of Changes in Tau Levels-Proof of Concept with HSP90 inhibitors", CURRENT ALZHEIMER RESEARCH, vol. 2, 2005, pages 231 - 238, XP008121926, DOI: doi:10.2174/1567205053585927
DICKEYPETRUCELLI: "Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression", MOLECULAR NEURODEGENERATION, vol. 1, 2006, pages 6
D'SOUZA, I.SCHELLENBERG, G.D.: "Regulation of tau isoform expression and dementia", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1739, 2005, pages 104 - 115, XP025329094, DOI: doi:10.1016/j.bbadis.2004.08.009
DUBOWCHIKWALKER, PHARM. THERAPEUTICS, vol. 83, 1999, pages 67 - 123
EDELMAN G. M. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 63, no. 1, 1969, pages 78 - 85
FORMICHI ET AL.: "Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease", J. CELL PHYSIOL., vol. 208, 2006, pages 39 - 46, XP002593166, DOI: doi:10.1002/JCP.20602
GILL ET AL., NATURE MED., vol. 9, 2003, pages 589 - 595
GODYN ET AL., PHARMACOLOGICAL REPORTS, vol. 68, 2016, pages 127 - 138
GOEDERT, M. ET AL.: "Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease", NEURON, vol. 3, 1989, pages 519 - 526, XP027463480, DOI: doi:10.1016/0896-6273(89)90210-9
GREENBERGDAVIES: "A preparation of Alzheimer paired helical filaments that diplays distinct tau proteins by polyacrylamide gel electrophoresis", PNAS, vol. 87, 1990, pages 5827 - 31
GREENBERGDAVIES: "A preparation of Alzheimer's paried helical filaments that displays distint tau proteins by polyacrylamide gel electrophoresis", PNAS, vol. 87, 1990, pages 5827 - 31
HAMPEL ET AL., ANN NEUROL., vol. 49, 2001, pages 545 - 546
HAMPEL ET AL.: "Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020", BIOCHEM. PHARMACOL., vol. 88, no. 4, 2014, pages 426 - 46
HANES ET AL.: "Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries", PNAS, vol. 95, 1998, pages 14130 - 14135, XP002165663, DOI: doi:10.1073/pnas.95.24.14130
HARDY ET AL.: "Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau", NATURE NEUROSCIENCE, vol. 1, no. 5, 1998, XP002258588, DOI: doi:10.1038/1565
HARDY, TRENDS NEUROSCI., vol. 20, 1997, pages 154 - 9
HARDYALLSOP: "Amyloid deposition as the central event in the aetiology of Alzheimer's disease", TIPS, vol. 12, 1991, XP023860717, DOI: doi:10.1016/0165-6147(91)90609-V
HARDYSELKOE: "The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics", SCIENCE, vol. 297, 2002, XP055310378, DOI: doi:10.1126/science.1072994
HARRISON ET AL., SCREENING OF PHAGE ANTIBODY LIBRARIES, vol. 26783-109, 1996, pages 83 - 109
HOGLUND ET AL., DEMENT. GERIATR. COGN. DISORD., vol. 19, 2005, pages 256 - 265
HU ET AL.: "Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay", AM. J. PATHOL., vol. 160, 2002, pages 1269 - 1278
HULSTAERT ET AL.: "Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF", NEUROLOGY, vol. 52, 1999, pages 1555 - 1562, XP009023746
HUSE WDSASTRY SIVERSON SAKANG ASALTING-MEES MBURTON DRBENKOVIV SJLERNER RA: "Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda", SCIENCE, vol. 246, 1989, pages 1275 - 1281, XP000083689, DOI: doi:10.1126/science.2531466
IQBAL ET AL., SUBGROUPS OF ALZHEIMER'S DISEASE BASED ON CEREBROSPINAL FLUID MOLECULAR MARKERS, vol. 58, 2005, pages 748 - 757
IQBALGRUNDKE-IQBAL: "Inhibition of Neurofibrillary Degeneration: A Promising Approach to Alzheimer's Disease and Other Tauopathies", CURRENT DRUG TARGETS, vol. 5, 2004, pages 495 - 502
IQBALGRUNDKE-LQBAL: "Developing pharmacological therapies for Alzheimer disease", CELL. MOL. LIFE SCI., vol. 64, 2007, pages 2234 - 2244, XP019536893, DOI: doi:10.1007/s00018-007-7221-9
IVANOVOVA ET AL.: "High-yield purification of fetal tau preserving its structure and phosphorylation", J. IMMUNOL. METHODS, vol. 339, 2008, pages 17 - 22, XP025504738, DOI: doi:10.1016/j.jim.2008.07.014
JOHNSON ET AL., ANTICANCER RES., vol. 15, 1995, pages 1387 - 93
JOHNSON GV ET AL.: "Tau phosphorylation in neuronal cell function and dysfunction", J. CELL SCI., vol. 117, 15 November 2004 (2004-11-15), pages 5721 - 9, XP055306280, DOI: doi:10.1242/jcs.01558
JOHNSON, G.WU, T. T., NUCLEIC ACIDS RES., vol. 28, 2000, pages 214 - 218
KAAS, Q.LEFRANC, M. P., CURRENT BIOINFORMATICS, vol. 2, 2007, pages 21 - 30
KAAS, Q.RUIZ, M.LEFRANC, M. P.: "T cell receptor and MHC structural data", NUCL. ACIDS. RES., vol. 32, 2004, pages D208 - D210
KABAT, E. A.WU, T. T.PERRY, H. M.GOTTESMANN, K. S.FOELLER, C.: "Sequences of Proteins of Immunological Interest", vol. I, 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, pages: 151,464
KANAI ET AL., ANN. NEUROL., vol. 44, pages 17 - 26
KANAI ET AL., NEUROSCI. LETT., vol. 267, 1999, pages 65 - 68
KIRKLAND ET AL., J. IMMUNOL, vol. 137, 1986, pages 3614
KONTSEKOVA ET AL.: "One-step method for establishing 8-azaguanine-resistant hybridomas suitable for preparation of triomas", J. IMMUNOL. METHODS, vol. 145, 1991, pages 247 - 250, XP023975161, DOI: doi:10.1016/0022-1759(91)90333-B
KONTSEKOVA ET AL.: "The effect of postfusion cell density on establishment of hybridomas", FOLIA BIOL., vol. 34, 1988, pages 18 - 22
KRAJCIOVA ET AL.: "Preserving free thios of intrinsically disordered tau protein without use of a reducing agent", ANALYTICAL BIOCHEMISTRY, vol. 383, 2008, pages 343 - 345, XP025585809, DOI: doi:10.1016/j.ab.2008.09.022
LARBIG ET AL.: "Screening for Inhibitors of Tau Protein Aggregation into Alzheimer Paired Helical Filaments: A Ligand Based Approach Results in Successful Scaffold Hopping", CURRENT ALZHEIMER RESEARCH, vol. 4, 2007, pages 315 - 323, XP008123572, DOI: doi:10.2174/156720507781077250
LASAGNA-REEVES ET AL., FASEB J., vol. 26, 2012, pages 1946 - 59
LAUR ET AL., BIOORG-MED-CHEM., vol. 3, no. 10, 1995, pages 1305 - 1304
LEFRANC M. P., IMMUNOLOGY TODAY, vol. 18, 1997, pages 509
LEFRANC M. P.: "The IMGT unique numbering for immunoglobulins, T-cell receptors, and Ig-like domains", THE IMMUNOLOGIST, vol. 7, no. 132-1 36, 1999, pages 1999 - 136
LEFRANC, M. P.POMMIE, C.RUIZ, M.GUIDICELLI, V.FOULQUIER, E.TRUONG, L.THOUVENIN-CONTET, V.LEFRANC, DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55 - 77
LEMOINE ET AL.: "Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains", ALZHEIMERS RES. THER., vol. 9, no. 1, 2017, pages 96
MATTSSON ET AL., J. ALZHEIMERS DIS., vol. 30, no. 4, 2012, pages 767 - 778
MATTSSON ET AL.: "AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease", EMBO MOL. MED., vol. 9, 2017, pages 1212 - 1223
MATTSSON ET AL.: "Comparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease", NEUROLOGY, vol. 5, 2018, pages e388 - e395
MOLDENHAUER ET AL., SCAND. J. IMMUNOL., vol. 32, 1990, pages 77
MOLLENHAUER ET AL., J. NEURAL. TRANSM., vol. 112, 2005, pages 933 - 948
MOREL ET AL., MOL. IMMUNOL., vol. 25, no. 1, 1988, pages 7
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
MORRISON, S. L. ET AL., PROC. NATL. ACAD SCI. USA, vol. 81, 1984, pages 6851 - 6855
MURRAY ET AL.: "Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias", ALZHEIMER'S RESEARCH & THERAPY, vol. 6, no. 1, 2014, pages 1, XP021193614, DOI: doi:10.1186/alzrt231
MURRAY ET AL.: "Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study", LANCET NEUROL., vol. 9, 2011, pages 785 - 96, XP055183487, DOI: doi:10.1016/S1474-4422(11)70156-9
NECULA ET AL.: "Cyanine Dye N744 Inhibits Tau Fibrillization by Blocking Filament Extension: Implications for the Treatment of Tauopathic Neurodegenerative Diseases", BIOCHEMISTRY, vol. 44, 2005, pages 10227 - 10237, XP055087111, DOI: doi:10.1021/bi050387o
NELSON ET AL.: "Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature", J. NEUROPATHOL. EXP. NEUROL., vol. 71, 2012, pages 362 - 81
NEUBERGER, M.S. ET AL., NATURE, vol. 314, 1985, pages 268 - 270
NEUWELT, E. A.: "Implication of the Blood-Brain Barrier and its Manipulation", vol. 1, 2, 1989, PLENUM PRESS
NEVILLE ET AL., BIOL. CHEM., vol. 264, 1989, pages 14653 - 14661
NG ET AL.: "Monoamine oxidase B inhibitor, selegiline, reduces F-THK5351 uptake in the human brain", ALZHEIMERS RES. THER., vol. 9, no. 1, 2017, pages 25
NISHIMURA ET AL., METHODS FIND. EXP. CLIN. PHARMACOL., vol. 20, 1998, pages 227 - 235
NOBLE ET AL.: "Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo", PNAS, vol. 102, no. 19, 2005, pages 6990 - 6995
ODDO ET AL.: "Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome", NEURON, vol. 43, 2004, pages 321 - 332
OLSSON ET AL.: "CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis", LANCET NEUROL., vol. 7, 2016, pages 673 - 84, XP029531930, DOI: doi:10.1016/S1474-4422(16)00070-3
OSSENKOPPELE ET AL.: "Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease", BRAIN, vol. 139, 2016, pages 1551 - 67
OSTROWITZKI ET AL., ALZHERIMERS RES THER., vol. 9, no. 1, 2017, pages 95
PAPANASTASSIOU ET AL., GENE THERAPY, vol. 9, 2002, pages 398 - 406
PICKHARDT ET AL.: "Screening for Inhibitors of Tau Polymerization", CURRENT ALZHEIMER RESEARCH, vol. 2, 2005, pages 219 - 226, XP009117693, DOI: doi:10.2174/1567205053585891
PLUCKTHUN: "The Pharmacology of Monoclonal Antibodies", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315
POPE M.E.SOSTE M.V.EYFORD B.A.ANDERSON N.L.PEARSON T.W., J. IMMUNOL. METHODS, vol. 341, no. 1-2, 2009, pages 86 - 96
PRESTA ET AL., J IMMUNOL, vol. 151, 1993, pages 2623
PRESTA, L.G.: "Engineering of therapeutic antibodies to minimize immunogenicity and optimize function", ADVANCED DRUG DELIVERY REVIEWS, vol. 58, no. 5-6, 2006, pages 640 - 656, XP024892146, DOI: doi:10.1016/j.addr.2006.01.026
RIECHMANN, L. ET AL., NATURE, vol. 332, 1988, pages 323 - 327
RISSIN, D.M. ET AL.: "Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations", NAT. BIOTECHNOL., vol. 28, no. 6, 2010, pages 555 - 559
ROBERSON ET AL.: "Reducing Endogenous Tau Ameliorates Amyloid β-induced Deficits in an Alzheimer's Disease Mouse Model", SCIENCE, vol. 316, 2007, pages 750
RUIZ, M.LEFRANC, M. P., IMMUNOGENETICS, vol. 53, 2002, pages 857 - 883
SAINT-AUBERT ET AL.: "Tau PET imaging: present and future directions", MOL. NEURODEGENER., vol. 12, 2017, pages 19
SAMBROOKRUSSELL, MOLECULAR CLONING: A LABORATORY MANUAL, 2001
SASTRY LALTING-MESS MHUSE WDSHORT JMSORGE JAHAY BNJANDA KDBENKOVIV SJLERNER RA: "Cloning of the immunological repertoire for generation of monoclonal catalytic antibodies: construction of a heavy chain variable region-specific cDNA library", PROC NATL ACAD SCI USA, vol. 86, 1989, pages 5728 - 5732, XP008026026, DOI: doi:10.1073/pnas.86.15.5728
SCHNEIDERMANDELKOW ET AL.: "Tau-Based Treatment Strategies in Neurodegenerative Diseases", NEUROTHERAPEUTICS, vol. 5, 2008, pages 443 - 457
SCHNEIDERMANDELKOW: "Tau-Based Treatment Strategies in Neurodegenerative Disease", NEUROTHERAPEUTICS, vol. 5, 2008, pages 443 - 457
SEABROOK ET AL.: "Beyond Amyloid the Next Generation of Alzheimer's Disease Therapeutics", MOLECULAR INTERVENTION, vol. 7, no. 5, 2007
SHIPTON ET AL.: "Tau Protein Is Required for Amyloid β-induced Impairment of Hippocampal Long-Term Potentiation", J. NEUROSCIENCE, vol. 31, no. 5, 2011, pages 1688 - 1692
SIMS ET AL., J. IMMUNOL., vol. 151, 1993, pages 2296
SLOANE ET AL.: "The Public Health Impact of Alzheimer's Disease, 2000-2050: Potential Implication of Treatment Advances", ANNU. REV. PUBLIC HEALTH, vol. 23, 2002, pages 213 - 31
STAHLI ET AL., METHODS IN ENZYMOLOGY, vol. 9, 1983, pages 242
SUNDERLAND ET AL., BIOL. PSYCHIATRY, vol. 46, 1999, pages 750 - 755
TABIRA, T.: "Immunization Therapy for Alzheimer disease: A Comprehensive Review of Active Immunization Strategies", TOHOKUJ. EXP. MED., vol. 220, 2010, pages 95 - 106, XP002599098, DOI: doi:10.1620/tjem.220.95
TANIGUCHI ET AL.: "Inhibition of Heparin-induced Tau Filament Formation by Phenothiazines, Polyphenols, and Porphyrins", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 9, 2005, pages 7614 - 7623, XP003014102, DOI: doi:10.1074/jbc.M408714200
TAPIOLA ET AL., NEUROSCI. LETT., vol. 280, 2000, pages 119 - 122
THORPE ET AL., CANCER RES., vol. 47, 1987, pages 5924 - 5931
TOLEDO ET AL., ACTA NEUROPATHOL., vol. 125, no. 5, 2013, pages 659 - 70
WALSHSELKOE: "Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease", NEURON, vol. 44, 2004, pages 181 - 193
WANG ET AL.: "Analysis of Cerebrospinal Fluid and [11 C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols", JAD, vol. 52, no. 4, 2016, pages 1403 - 13
WANG ET AL.: "Tau in physiology and pathology", NATURE REVIEWS, vol. 17, 2016, pages 22 - 35
WAWRZYNCZAK ET AL.: "Immunoconjugates: Antibody Conjugates in Radiolmagery and Therapy of Cancer", 1987, OXFORD U. PRESS
WENNSTROM ET AL.: "The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies", PLOSONE, vol. 10, no. 8, 2015, pages e0135458
WISCHIK ET AL.: "Selective inhibition of Alzheimer's disease-like tau aggregation by phenothiazines", PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 11213 - 11218, XP002067057, DOI: doi:10.1073/pnas.93.20.11213
WU JLI L: "Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications", JOURNAL OF BIOMEDICAL RESEARCH, vol. 30, no. 5, 2016, pages 361 - 372
ZETTERBERG ET AL., ALZHEIMERS RES. THER., vol. 5, no. 2, 2007, pages 9
ZHANG ET AL.: "Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model", PNAS, vol. 102, no. 1, 2005, pages 227 - 231, XP002539191, DOI: doi:10.1073/PNAS.0406361102
ZILKA ET AL.: "Chaperone-like Antibodies Targeting Misfolded Tau Protein: New Vistas in the Immunotherapy of Neurodegenerative Foldopathies", JOURNAL OF ALZHEIMER'S DISEASE, vol. 15, 2008, pages 169 - 177
ZILKA ET AL.: "Chaperon-like Antibodies Targeting Misfolded Tau Protein: New Vistas in the Immunotherapy of Neurodegenerative Foldopathies", JOURNAL OF ALZHEIMER'S DISEASE, vol. 15, 2008, pages 169 - 177

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11643457B2 (en) 2013-03-13 2023-05-09 Prothena Biosciences Limited Tau immunotherapy
US11492393B2 (en) 2016-05-02 2022-11-08 Prothena Biosciences Limited Tau immunotherapy
US11584791B2 (en) 2016-05-02 2023-02-21 Prothena Biosciences Limited Antibodies recognizing tau
US11958896B2 (en) 2017-05-02 2024-04-16 Prothena Biosciences Limited Antibodies recognizing tau
US11926659B2 (en) 2019-03-03 2024-03-12 Prothena Biosciences Limited Antibodies recognizing tau
WO2021048619A2 (en) 2019-09-09 2021-03-18 Axon Neuroscience Se Biomarkers and treatments of alzheimer's disease and mild cognitive impairment
WO2022132923A1 (en) * 2020-12-16 2022-06-23 Voyager Therapeutics, Inc. Tau binding compounds
WO2022176959A1 (en) * 2021-02-19 2022-08-25 Eisai R&D Management Co., Ltd. Anti-pt217 tau antibody

Also Published As

Publication number Publication date
CN112236452A (zh) 2021-01-15
RU2020135052A (ru) 2022-04-29
WO2019186276A8 (en) 2020-10-15
EP3774887A2 (en) 2021-02-17
SG11202008098TA (en) 2020-10-29
JP2021520777A (ja) 2021-08-26
MX2020009991A (es) 2020-10-14
BR112020018868A2 (pt) 2021-01-26
KR20200144551A (ko) 2020-12-29
CA3095443A1 (en) 2019-10-03
WO2019186276A3 (en) 2020-02-27
IL277577A (en) 2020-11-30
AU2019244481A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
AU2019244481A1 (en) Antibody-based methods of detecting and treating Alzheimer's disease
US11319363B2 (en) Humanized tau antibodies in Alzheimer's disease
CN108034005B (zh) 识别Tau的磷酸化特异抗体
US20200369754A1 (en) Binding molecules that specifically bind to tau
US20210122810A1 (en) Binding molecules that specifically bind to tau
US20230151083A1 (en) Anti-phf-tau antibodies and uses thereof
CN113891746A (zh) 焦谷氨酸淀粉样蛋白-β的抗体及其用途
US20240150451A1 (en) Anti-tau antibodies and uses thereof
EP3334453A2 (en) Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
US20210139568A1 (en) Antibody-based methods of detecting and treating alzheimer's disease
US20230365665A1 (en) ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES
WO2022060236A1 (en) ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED α-SYNUCLEIN AGGREGATES
EP4229082A1 (en) Antibodies binding to alpha-synuclein for therapy and diagnosis
TW202346865A (zh) 檢定
EA039569B1 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2020551506

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3095443

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019244481

Country of ref document: AU

Date of ref document: 20190327

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020018868

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2019732436

Country of ref document: EP

Effective date: 20201028

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19732436

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112020018868

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200916